Kirk Heyne is an Oncology physician affiliated with Houston Methodist. OpenAlex indexes 40 publications with 908 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
27.7%Serotonin-3 Receptor Antagonist10.3%Ondansetron Hcl62%Ondansetron Odt38%Part D≥29 patientsCorticosteroid6.6%Prednisone100%Part D≥11 patients+ 3 more classes in this area
Cancer & immunology
20.5%Kinase inhibitor6.2%Lenvima46%Cabometyx27%Ibrance27%Part D<11 patientsCytochrome P450 17A1 Inhibitor5%Abiraterone Acetate100%Part D<11 patients+ 3 more classes in this area
Nervous system
18.8%SNRI4.8%Duloxetine Hcl100%Part D<11 patientsOpioid Agonist4%Morphine Sulfate Er57%Morphine Sulfate43%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Incidental Combined Hepatocellular-Cholangiocarcinoma in Liver Transplant Recipients: A Matched Cohort Study
Transplant International
2026 - Molecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation
JCO Precision Oncology
2026 - Liver transplantation in patients with history of extra-hepatic malignancies
Frontiers in Transplantation
2026 - Prospective Tumor Molecular Profiling After Liver Transplantation
American Journal of Transplantation
2026 - Cell cycle pathway alterations predict outcomes post-liver transplantation for hepatocellular carcinoma
Frontiers in Transplantation
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”